Mer­ck nabs ap­proval for Keytru­da com­bo in kid­ney can­cer af­ter prov­ing it can ex­tend sur­vival

The FDA and out­side ex­perts have spent the last year talk­ing about can­cers where the ben­e­fits of Keytru­da and oth­er im­munother­a­pies are ques­tion­able, but in some cas­es, the re­sults speak for them­selves.

The FDA on Wednes­day ap­proved a com­bi­na­tion of Mer­ck’s Keytru­da and Ei­sai’s TKI in­hibitor Lenvi­ma for treat­ing pa­tients with ad­vanced re­nal cell car­ci­no­ma, the most com­mon form of kid­ney can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER